Evidence map›Paper›PMID 36500678›Full record

ArticleMolecules (Basel, Switzerland)2022

Novel Approaches for the Solid-Phase Synthesis of Dihydroquinazoline-2(1

Qiong Wang, Ying Pan, Hongjun Luo, Yanmei Zhang, Fenfei Gao, Jinzhi Wang, Jinhong Zheng

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qiong WangDepartment of Chemistry, Shantou University Medical College, 22 Xinling Road, Shantou 515041, China.
Ying PanDepartment of Chemistry, Shantou University Medical College, 22 Xinling Road, Shantou 515041, China.
Hongjun LuoBio-Analytical Laboratory, Shantou University Medical College, 22 Xinling Road, Shantou 515041, China.
Yanmei ZhangDepartment of Pharmacology, Shantou University Medical College, 22 Xinling Road, Shantou 515041, China.
Fenfei GaoDepartment of Pharmacology, Shantou University Medical College, 22 Xinling Road, Shantou 515041, China.ORCID 0000-0003-4144-8891
Jinzhi WangDepartment of Chemistry, Shantou University Medical College, 22 Xinling Road, Shantou 515041, China.
Jinhong ZhengDepartment of Chemistry, Shantou University Medical College, 22 Xinling Road, Shantou 515041, China.

Funding

the Guangdong Medical Science and technology research foundation of China A201732the Natural Science Foundation of Guangdong Province of China 2019A1515012101
6 · The paper itself

Abstract

In the design of antineoplastic drugs, quinazolinone derivatives are often used as small molecule inhibitors for kinases or receptor kinases, such as the EGFR tyrosine kinase inhibitor gefitinib, p38MAP kinase inhibitor

Indexed as

Antineoplastic AgentsOvarian NeoplasmsBromodomain Containing ProteinsCell Cycle ProteinsCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorFemaleHumansMolecular Docking SimulationMolecular StructureNuclear ProteinsProtein Kinase InhibitorsSolid-Phase Synthesis TechniquesStructure-Activity RelationshipAntineoplastic AgentsBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsNuclear ProteinsProtein Kinase InhibitorsTranscription FactorsADMETanticancerantioxidationbioinformaticsdihydroquinazoline-2(1H)-onesolid-phase synthesis

Identifiers

PMID36500678
PMCPMC9737648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.